SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences
SOTIO will obtain rights to deploy LCBs ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.
- SOTIO will obtain rights to deploy LCBs ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.
- The deal includes upfront and near-term milestones worth up to $29.5 million, subject to exercise of the options and achievement of success-based milestones.
- At SOTIO we are building an innovative pipeline of ADC programs and plan IND filing for our lead program SOT102 by the end of 2021.
- The licensing agreement with our new, experienced partner LegoChem allows us to broaden our oncology pipeline with additional programs and solid tumor targets.